Gongshi

Scholar Rock to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, February 28, 2024
Oncology, Health, Neurology, Genetics, Pharmaceutical, Cardiology, Biotechnology, Rock, Conference, SMA, Webcast, Gongshi, Obesity

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in and attend the following upcoming investor conferences in March:

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in and attend the following upcoming investor conferences in March:
    TD Cowen 44th Annual Health Care Conference: Scholar Rock is scheduled to participate in a fireside chat at 9:10 a.m.
  • BMO Biopharma Spotlight Series: Obesity Day: Scholar Rock is scheduled to participate in a panel discussion on Wednesday, March 20 in New York City.
  • A live webcast of the Cowen event may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .
  • An archived replay of the webcast will be available on the Company’s website for approximately 90 days.

Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer

Retrieved on: 
Thursday, February 15, 2024
Oncology, Health, Neurology, Genetics, Pharmaceutical, Cardiology, Biotechnology, Alexion Pharmaceuticals, Ophthalmology, Indiana University, Metabolism, Rock, Growth, Diabetes, MBA, Allergan, Doctor of Philosophy, SMA, Genentech, Roche, University, Therapy, MPH, Medicine, American University, Baylor College of Medicine, Gongshi, Master of Science, Obesity, Research, Spinal muscular atrophy, Amgen, Management

“We are pleased to welcome Katie to Scholar Rock’s Board of Directors at a pivotal time when the company is preparing for the potential launch of apitegromab next year,” said David Hallal, Chairman of the Board of Scholar Rock.

Key Points: 
  • “We are pleased to welcome Katie to Scholar Rock’s Board of Directors at a pivotal time when the company is preparing for the potential launch of apitegromab next year,” said David Hallal, Chairman of the Board of Scholar Rock.
  • Katie joining our Board reflects the continued evolution of Scholar Rock, and as part of this process, Amir Nashat will be stepping down from the Board at this year’s annual shareholder meeting.
  • Prior to joining Denali, Ms. Peng managed a neurology, ophthalmology, immunology, and rare disease portfolio representing approximately $14 billion in revenue at Genentech.
  • “I am thrilled to join Scholar Rock’s Board of Directors as the company prepares for its first potential commercial launch of apitegromab.

Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia

Retrieved on: 
Thursday, January 25, 2024
Research, Infectious Diseases, Diabetes, Fitness & Nutrition, Cardiology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Senior, Obesity, Bone density, Facial muscles, Poster, Publication, Rock, Weight loss, Center of mass, Gongshi, SMA, Abstract (summary), Pharmaceutical industry

Scholar Rock will present preclinical data evaluating SRK-439 in combination with GLP-1 receptor agonists in obesity to maintain lean mass and enhance fat mass loss.

Key Points: 
  • Scholar Rock will present preclinical data evaluating SRK-439 in combination with GLP-1 receptor agonists in obesity to maintain lean mass and enhance fat mass loss.
  • “Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as effective treatments with rapid implementation for obesity, a recognized global epidemic.
  • However, the weight loss resulting from GLP-1 RA treatment has been shown to be associated with significant loss of lean muscle mass.
  • The presentation will be made available in the Publications & Posters section of Scholar Rock’s website following the presentation.

Scholar Rock Provides Corporate Update and Highlights Priorities for 2024

Retrieved on: 
Thursday, January 4, 2024
Research, Neurology, Diabetes, Clinical Trials, Cardiology, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Conference, Cure, IND, SAPPHIRE, Spinal muscular atrophy, Clinical trial, Obesity, Standard of care, Annual general meeting, Gongshi, Consequence, Myostatin, DRAGON, Webcast, MPH, Patient, Rock, SMN, SMA, Renal cell carcinoma, SITC, Pharmaceutical industry

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2024.

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for 2024.
  • Planning to announce Phase 3 SAPPHIRE clinical trial topline data in 4Q 2024.
  • Scholar Rock management will highlight these updates in a corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. PT (4:30 p.m.
  • A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .

Scholar Rock to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, December 19, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Webcast, Conference, Rock, Gongshi

Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. PT (4:30 p.m.

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. PT (4:30 p.m.
  • ET).
  • A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .
  • An archived replay of the webcast will be available on the Company’s website for approximately 90 days.

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, December 15, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Plan, RSU, Employment, Rock, Financial adviser, Gongshi

The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (“The Plan”) and the award agreements thereunder.

Key Points: 
  • The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (“The Plan”) and the award agreements thereunder.
  • The Plan, which was adopted by the Company’s board of directors on June 16, 2022, is used exclusively for the grant of equity awards to individuals who were not previously employees of Scholar Rock, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Scholar Rock, pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The options have an exercise price of $18.07, which is equal to the closing price of Scholar Rock’s common stock on December 11, 2023.
  • All vesting related to inducement awards is subject to the employees’ continuing service at the Company through the applicable vesting date.

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, November 17, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Plan, RSU, Employment, Rock, Financial adviser, Gongshi

The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (“The Plan”) and the award agreements thereunder.

Key Points: 
  • The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (“The Plan”) and the award agreements thereunder.
  • The Plan, which was adopted by the Company’s board of directors on June 16, 2022, is used exclusively for the grant of equity awards to individuals who were not previously employees of Scholar Rock, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Scholar Rock, pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The options have an exercise price of $9.88, which is equal to the closing price of Scholar Rock’s common stock on November 13, 2023.
  • All vesting related to inducement awards is subject to the employees’ continuing service at the Company through the applicable vesting date.

Scholar Rock Reports Third Quarter 2023 Financial Results and Highlights Business Progress

Retrieved on: 
Tuesday, November 7, 2023
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Gongshi, Myostatin, SMN, SAPPHIRE, IND, PIN, MPH, Obesity, Pembrolizumab, Maintenance, SITC, Rock, DRAGON, Clinical trial, Neoplasm, Webcast, Annual general meeting, ORR, Renal cell carcinoma, SMA, Patient, Pharmaceutical industry, Cryptocurrency

The Company announced that it completed enrollment in September 2023, with topline data expected in the fourth quarter of 2024.

Key Points: 
  • The Company announced that it completed enrollment in September 2023, with topline data expected in the fourth quarter of 2024.
  • Research and development expense was $30.3 million for the quarter ended September 30, 2023, compared to $33.4 million for the quarter ended September 30, 2022.
  • General and administrative expense was $13.3 million for the quarter ended September 30, 2023, compared to $10.5 million for the quarter ended September 30, 2022.
  • A live webcast of the conference call will be available on the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .

Scholar Rock to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, November 2, 2023
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Gongshi, Rock, Conference, Webcast, Piper Sandler Companies, Pharmaceutical industry

Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences:

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences:
    Truist Securities BioPharma Symposium on Thursday, November 9, 2023, from 10:45-11:30 a.m.
  • Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023, from 12:30-12:55 p.m.
  • A live webcast of the Piper Sandler event may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .
  • An archived replay of the webcast will be available on the Company’s website for approximately 90 days.

Scholar Rock to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023

Retrieved on: 
Monday, October 23, 2023
Biotechnology, Pharmaceutical, Health, Gongshi, Rock, Webcast, PIN, Pharmaceutical industry, Online shopping

Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its third quarter 2023 financial results and provide a business update on Tuesday, November 7, 2023, at 8:00 a.m.

Key Points: 
  • Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its third quarter 2023 financial results and provide a business update on Tuesday, November 7, 2023, at 8:00 a.m.
  • To access the conference call by phone, participants may register here to receive the dial-in number and unique PIN.
  • A live webcast of the conference call will be available on the Investors & Media section of the Scholar Rock website at http://investors.scholarrock.com .
  • An archived replay of the webcast will be available for approximately 90 days following the call.